Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| KAPA | 8-K | bullish | 6/10 | Kairos Pharma reported positive interim Phase 2 data for ENV-105 (carotuximab) in metastatic castration-resistant prosta | Oct 6, 2026 |
| INDV | 8-K | neutral | 3/10 | Indivior filed an 8-K supplementing its joint proxy statement/prospectus for the pending merger with Supernus, adding su | Oct 6, 2026 |
| ADIA | 8-K | neutral | 4/10 | Adia Med, Inc. completed the sale of a 30% membership interest in its subsidiary Adia Labs LLC to Live Oak Health LLC (d | Oct 5, 2026 |
| EQ | 8-K | neutral | 3/10 | Equillium received regulatory clearance from Australian authorities (HREC and TGA) to begin a Phase 1 clinical trial of | Oct 5, 2026 |
| IOVA | 8-K | neutral | 4/10 | Iovance Biotherapeutics filed an 8-K to update its corporate presentation, highlighting strong Q2 2026 revenue of ~$99M | Oct 5, 2026 |
| NRXP | 8-K | bullish | 6/10 | NRx Pharmaceuticals' subsidiary, NRx Defense Systems, was awarded an $11.2 million prime contract from DARPA to conduct | Oct 5, 2026 |
| ADIA | 8-K | neutral | 5/10 | Adia Med, Inc. filed a declaratory judgment action in Florida state court seeking to quiet title to 29,059,792 shares (3 | Oct 5, 2026 |
| OSTX | 8-K | neutral | 5/10 | OS Therapies appointed Frank Knuettel II as CFO and Kerry Clem as CCO, replacing outgoing CFO Christopher Acevedo. The p | Oct 5, 2026 |
| USNA | 8-K | neutral | 3/10 | USANA entered into a First Amendment to its existing credit agreement with Bank of America, N.A. and other lenders. The | Oct 5, 2026 |
| KRRO | 8-K | neutral | 4/10 | Korro Bio dosed the first cohort of healthy volunteers in its Phase 1/2 ANCHOR trial for KRRO-121, a GalNAc-conjugated R | Oct 5, 2026 |
| ABBV | 8-K | neutral | 4/10 | AbbVie filed an 8-K updating its full-year 2026 adjusted diluted EPS guidance to $13.76-$13.96, incorporating a $216 mil | Oct 5, 2026 |
| PMVP | 8-K | bullish | 6/10 | PMV Pharmaceuticals appointed Dr. Matthew Eckler to its Board of Directors, with the press release also announcing the c | Oct 5, 2026 |
| JAGX | 8-K | bearish | 7/10 | Jaguar Health declared a special one-time dividend of Series R Convertible Preferred Stock, with each share converting i | Oct 5, 2026 |
| MBRX | 8-K | neutral | 2/10 | Moleculin Biotech filed an 8-K on October 5, 2026, to furnish an investor presentation (Exhibit 99.1) posted on its webs | Oct 5, 2026 |
| COYA | 8-K | neutral | 4/10 | Coya Therapeutics announced full enrollment of 120 patients in its Phase 2/3 ALSTARS trial (NCT07161999) evaluating COYA | Oct 5, 2026 |
| IMNM | 8-K | bullish | 6/10 | Immunome entered into Amendment No. 4 to its License Agreement with Bristol-Myers Squibb, paying $20M in cash and issuin | Oct 5, 2026 |
| BNTC | 8-K | neutral | 4/10 | Benitec announced receipt of formal FDA feedback from a Type C meeting regarding the BB-301 pivotal study design. The FD | Oct 5, 2026 |
| PCVX | 8-K | bullish | 7/10 | Vaxcyte reported positive topline Phase 3 data from the OPUS-1 pivotal trial of VAX-31, its 31-valent pneumococcal conju | Oct 5, 2026 |
| RZLT | 8-K | mixed | 6/10 | Rezolute announced that the FDA recommended a pre-BLA meeting as a precursor to submitting a Biologics License Applicati | Oct 5, 2026 |
| HROW | 8-K | bullish | 7/10 | Harrow closed its acquisition of worldwide rights to TYRVAYA (varenicline solution) nasal spray from Viatris, excluding | Oct 5, 2026 |
| INSM | 8-K | neutral | 4/10 | Insmed announced CFO Sara Bonstein will step down on October 30, 2026, with a search underway for a successor. The compa | Oct 5, 2026 |
| ALEC | 8-K | bullish | 7/10 | Alector entered an exclusive global license agreement with Genentech for its AL050 GCase enzyme replacement therapy prog | Oct 5, 2026 |
| TNXP | 8-K | bearish | 6/10 | Tonix received a Paragraph IV ANDA notice from Dr. Reddy's Laboratories seeking FDA approval for a generic version of it | Oct 2, 2026 |
| LNTH | 8-K | neutral | 4/10 | Lantheus filed an 8-K disclosing supplemental proxy disclosures to settle three shareholder lawsuits and 16 demand lette | Oct 2, 2026 |
| LEEEF | 8-K | neutral | 3/10 | Leef Brands appointed Hirsh Jain as an independent director, expanding the board to six members, while CFO Kevin Wilson | Oct 2, 2026 |
| SILO | 8-K | neutral | 4/10 | Silo Pharma acquired software, technology, and related intellectual property (the 'Klone' brand web-based tools) from No | Oct 2, 2026 |
| CING | 8-K | neutral | 3/10 | Cingulate Inc. filed an 8-K to disclose an amendment to the employment agreement of its Chief Medical Officer, Matthew N | Oct 2, 2026 |
| BYSI | 8-K | bearish | 8/10 | BeyondSpring received a Nasdaq deficiency notice on September 29, 2026, for failing to maintain a minimum $35 million ma | Oct 2, 2026 |
| IPSC | 8-K | neutral | 4/10 | Century Therapeutics presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diab | Oct 2, 2026 |
| SRZN | 8-K | bullish | 7/10 | Surrozen received FDA clearance of its IND application for SZN-8141, a bifunctional Wnt agonist/VEGF antagonist antibody | Oct 2, 2026 |